BRISTOL MYERS SQUIBB CO (CELG-RI) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-08

Key Insights

All 11 director nominees were elected with strong shareholder support, with Phyllis R. Yale receiving the highest approval at 99.4% and Christopher S. Boerner receiving the lowest at 95.2%, indicating stable governance and investor confidence in board composition.
The advisory vote on named executive officer compensation passed comfortably with 95.3% support (1.46B votes for vs 72.5M against), suggesting shareholders are satisfied with current management incentive structures despite the failed independent chair proposal.
Shareholders rejected the proposal to require an independent board chairperson with 72.4% voting against it, demonstrating investor acceptance of Bristol-Myers Squibb's current board leadership structure and governance practices.
The 2026 stock award and incentive plan received strong approval at 95.8%, providing management with continued flexibility for equity-based compensation and employee retention initiatives.

Want the newest filings?

This analysis covers the filing from 2026-05-08. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-30

Bristol-Myers Squibb announced Q1 2026 financial results on April 30, 2026, with earnings press release and presentation materials filed as exhibits to the 8-K.
The filing includes non-GAAP financial measures with reconciliations to GAAP figures, indicating the company is presenting adjusted metrics alongside standard accounting results.
Company maintains diverse debt structure with seven outstanding note issues ranging from 2030 to 2055 maturities, plus Celgene Contingent Value Rights still trading on NYSE as legacy acquisition-related securities.
The 8-K is a routine quarterly earnings disclosure with no material agreements, executive changes, or significant corporate events reported in Items 2.02 and 7.01.

Other reports for BRISTOL MYERS SQUIBB CO

Insider Trading Quarterly Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.